What Are the Side Effects of Selank?

What Is Selank?

Selank is a heptapeptide (7 amino acids) derived from tuftsin, an immunomodulatory peptide found in the body. Originally developed in Russia as an anxiolytic and immune-supporting peptide, it gained research attention for its ability to reduce anxiety without sedation, improve cognitive function, and support immune health. Unlike traditional anxiolytics (benzodiazepines, SSRIs), Selank has a different mechanism of action and safety profile.

General Safety Profile of Selank

Selank has demonstrated a favorable safety profile across multiple clinical trials and observational studies. The peptide does not appear to be habit-forming, has no known dependence potential, shows no significant organ toxicity, has minimal interactions with other medications, and does not impair cognitive function. The most compelling evidence comes from Russian clinical research spanning over two decades, where serious adverse effects are essentially absent at therapeutic doses.

Common Mild Side Effects

The most frequently reported side effects are mild and transient. Nausea occurs in 5-10% of users, typically mild and diminishing after first dose. Headache appears in 3-7% of users, usually attributed to improved cerebral blood flow. Transient mood changes—brief irritability or restlessness—occur in <5%, typically resolving within hours. Sleep disturbances are rare but possible at evening doses. These effects almost never persist beyond 2-3 doses.

Injection Site Reactions

Like all peptides administered via injection, Selank may cause local injection site reactions. Mild erythema (redness) at injection site is most common. Slight soreness or itching at site resolves within hours to days. Swelling or bruising is rare unless blood vessel punctured. Using proper aseptic technique, rotating injection sites, and warming the solution before injection significantly reduces these reactions.

Allergic Reactions: Frequency and Risk Factors

True IgE-mediated allergic reactions to Selank are extremely rare, estimated <0.1% incidence. However, histamine release reactions—flushing, itching, mild rash—occur more commonly in 1-3% of users, particularly in those with mast cell activation syndrome or high baseline histamine. Pre-treatment with antihistamines (H1 + H2 blockers) prevents histamine reactions in nearly all susceptible individuals. Anaphylaxis has not been documented in research.

Hormonal and Endocrine Effects

Selank does not significantly alter cortisol, testosterone, thyroid hormones, or other major endocrine parameters at therapeutic doses. Some research suggests modest improvements in cortisol regulation (flattening of dysfunctional patterns), but this is a beneficial effect rather than an adverse one. No cases of hypogonadism, thyroid dysfunction, or adrenal suppression have been reported. Long-term endocrine effects remain understudied in humans.

Neurological Side Effects

Headache is the most common neurological effect, typically mild and transient. Dizziness or vertigo are rare. Seizures have not been reported even in epileptic populations. Peripheral neuropathy has not been documented. The peptide does not appear to increase seizure risk or alter seizure threshold. Tremor, ataxia, or other movement disorders are absent from clinical literature.

How Common Are Serious Adverse Events?

In published clinical trials and observational studies spanning thousands of patients, serious adverse events (hospitalizations, permanent injury, organ damage) are virtually absent. The absence of serious events across decades of use—particularly in Russian clinical practice where it has been used extensively—strongly suggests an inherently safe compound at therapeutic doses. Individual case reports of severe effects are extremely rare and often lack clear causation.

Comparing Selank to Other Anxiolytics

Unlike benzodiazepines, Selank causes no cognitive impairment, dependence, or respiratory depression. Unlike SSRIs, it causes no weight gain, sexual dysfunction, or withdrawal symptoms. Unlike herbal anxiolytics (kava, passionflower), it has no hepatotoxicity risk. This favorable comparison to standard anxiolytics explains growing research interest and clinical adoption, particularly in countries where it's approved for medical use.

Dose-Response Effects and Overdose

Therapeutic doses of Selank are 250-500 mcg daily. Higher doses (1000+ mcg) have been studied; even these show tolerability, though no additional benefit. No overdose toxicity syndrome has been described. Animal studies suggest very high doses (far above therapeutic levels) are tolerated without lethality, indicating a wide safety margin. The lack of dose-dependent serious effects is reassuring.

Drug Interactions and Contraindications

Selank has no known serious interactions with medications. It may modestly potentiate sedating medications if they're combined, but this is mild and avoidable through dose timing. No contraindications with antidepressants, antihistamines, or common medications. Pregnancy and lactation: not studied in humans, so caution recommended. Active psychosis or severe psychiatric instability should prompt medical consultation before use.